ライフサイエンスコーパス: hepatitis C antibody

1 lysis patients, including those positive for hepatitis C antibody.

2 ceiving a renal transplant were positive for hepatitis C antibodies.

3 risk drug-using practices, as was found with hepatitis C antibodies.

4 containing the non-specific Ab (anti-HCV for Hepatitis C) antibodies.

5 Among those testing positive for hepatitis C antibody, 78% either had a transfusion or ha

6 study was to estimate the prevalence of anti-hepatitis C antibody and evaluate factors associated wit

7 Anti-hepatitis C antibody and hepatitis B antigen were presen

8 systems received surveys requesting data on hepatitis C antibody and viremic prevalence.

9 eptance were for male donor sex, blood type, hepatitis C antibody, donor age, left ventricular hypert

10 The corresponding odds ratio comparing hepatitis C antibodies (HCV Ab) (+) to HCV Ab (-) partic

11 se of hepatitis B core antibody (HBcAb+) and hepatitis C antibody (HCV Ab+) positive donors represent

12 Tests included hepatitis C antibody, HCV RNA, HCV genotype (nucleic aci

13 NA level, lower pretreatment CD4 cell count, hepatitis C antibody, less education, and recent nonadhe

14 ansplantation compared with patients who are hepatitis C antibody negative.

15 e, suffered brain death secondary to trauma, hepatitis C antibody-negative, not categorized as high r

16 ce, more amino acid mixtures (all P < .001), hepatitis C antibody negativity (P = .05), and black rac

17 Renal transplant recipients who are hepatitis C antibody positive do not have an increased r

18 tis B surface antigen was 8% (48 of 574) and hepatitis C antibody positivity was 3% (15 of 574).

19 line medical condition, diagnosis, and donor hepatitis C antibody status impacted 1- and 5-year survi

20 d models were used to evaluate the impact of hepatitis C antibody status on the study endpoints.

21 Testing begins with a hepatitis C antibody test, followed, when reactive, by a

22 om a cohort of real-world patients receiving hepatitis C antibody therapy with LDF/SOF +/- RBV suppor

23 3-7.9) among controls, and the prevalence of hepatitis C antibodies was 6.5% (95% CI 4.3-9.4) among c

24 A level, serum protein electrophoresis, and hepatitis C antibodies were within normal limits.

25 A level, serum protein electrophoresis, and hepatitis C antibodies were within normal limits.

26 Only one child out of 12 was positive for hepatitis C antibody yet, subsequent PCR testing was neg